NO2009007I1 - Robenakoksib, et salt, en ester eller prodrug derav - Google Patents

Robenakoksib, et salt, en ester eller prodrug derav

Info

Publication number
NO2009007I1
NO2009007I1 NO2009007C NO2009007C NO2009007I1 NO 2009007 I1 NO2009007 I1 NO 2009007I1 NO 2009007 C NO2009007 C NO 2009007C NO 2009007 C NO2009007 C NO 2009007C NO 2009007 I1 NO2009007 I1 NO 2009007I1
Authority
NO
Norway
Prior art keywords
robenacoxib
prodrug
ester
salt
Prior art date
Application number
NO2009007C
Other languages
English (en)
Other versions
NO2009007I2 (no
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26736901&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2009007(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO2009007I1 publication Critical patent/NO2009007I1/no
Publication of NO2009007I2 publication Critical patent/NO2009007I2/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/40—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/42—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by saturated carbon chains
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO2009007C 1997-08-28 2009-03-26 Robenakoksib, eller et farmasøytisk akseptabelt salt derav, eller en farmasøytisk akseptabel in vivo hydrolyserbar ester derav NO2009007I2 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6983797P 1997-08-28 1997-08-28
US5780397P 1997-08-28 1997-08-28
PCT/EP1998/005414 WO1999011605A1 (en) 1997-08-28 1998-08-26 Certain 5-alkyl-2-arylaminophenylacetic acids and derivatives

Publications (2)

Publication Number Publication Date
NO2009007I1 true NO2009007I1 (no) 2009-04-06
NO2009007I2 NO2009007I2 (no) 2010-06-07

Family

ID=26736901

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20000943A NO326196B1 (no) 1997-08-28 2000-02-25 5-alkyl-2-arylaminofenyleddiksyrer og salter eller estere derav, anvendelse derav, farmasøytisk sammensetning samt fremgangsmåte for fremstilling av forbindelsene.
NO2009007C NO2009007I2 (no) 1997-08-28 2009-03-26 Robenakoksib, eller et farmasøytisk akseptabelt salt derav, eller en farmasøytisk akseptabel in vivo hydrolyserbar ester derav

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO20000943A NO326196B1 (no) 1997-08-28 2000-02-25 5-alkyl-2-arylaminofenyleddiksyrer og salter eller estere derav, anvendelse derav, farmasøytisk sammensetning samt fremgangsmåte for fremstilling av forbindelsene.

Country Status (34)

Country Link
US (5) US6291523B1 (no)
EP (1) EP1007505B1 (no)
JP (1) JP3704470B2 (no)
KR (1) KR100637296B1 (no)
CN (1) CN1140500C (no)
AR (1) AR015157A1 (no)
AT (1) ATE237580T1 (no)
AU (1) AU743371B2 (no)
BR (1) BR9812010B1 (no)
CA (1) CA2298033C (no)
CO (1) CO4960662A1 (no)
CY (1) CY2007020I2 (no)
CZ (1) CZ298522B6 (no)
DE (4) DE122009000013I1 (no)
DK (1) DK1007505T3 (no)
ES (1) ES2197508T3 (no)
FR (1) FR09C0011I2 (no)
HU (1) HU225774B1 (no)
ID (1) ID23953A (no)
IL (2) IL134498A0 (no)
LU (2) LU91346I2 (no)
MY (1) MY127881A (no)
NL (1) NL300379I2 (no)
NO (2) NO326196B1 (no)
NZ (1) NZ502669A (no)
PE (1) PE108099A1 (no)
PL (1) PL194480B1 (no)
PT (1) PT1007505E (no)
RU (1) RU2186762C2 (no)
SI (1) SI1007505T1 (no)
SK (1) SK283773B6 (no)
TR (1) TR200000447T2 (no)
TW (1) TWI250142B (no)
WO (1) WO1999011605A1 (no)

Families Citing this family (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040072889A1 (en) * 1997-04-21 2004-04-15 Pharmacia Corporation Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia
CO4960662A1 (es) * 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
DE69922688T2 (de) * 1998-11-02 2005-12-01 Merck & Co. Inc. Zusammensetzungen aus einem 5ht1b/1d agonisten und einem selektiven cox-2 hemmer zur behandlung von migräne
US20040053900A1 (en) * 1998-12-23 2004-03-18 Pharmacia Corporation Method of using a COX-2 inhibitor and an aromatase inhibitor as a combination therapy
US20040122011A1 (en) * 1998-12-23 2004-06-24 Pharmacia Corporation Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy
GB9922830D0 (en) * 1999-09-27 1999-11-24 Novartis Ag Processes
PE20010921A1 (es) 1999-12-08 2001-09-10 Pharmacia Corp Composiciones inhibidoras de ciclooxigenasa-2 que tienen un inicio rapido del efecto terapeutico
AR030630A1 (es) * 2000-09-11 2003-08-27 Novartis Ag Composiciones farmaceuticas
WO2002040018A1 (en) * 2000-11-14 2002-05-23 Alcon, Inc. Treatment of glaucoma and ocular hypertension
US20050264906A1 (en) * 2004-05-25 2005-12-01 Haratsch Erich F Method and apparatus for reduced-state Viterbi detection in a read channel of a magnetic recording system
US7656959B2 (en) 2001-04-13 2010-02-02 Agere Systems Inc. Pipelined decision-feedback unit in a reduced-state viterbi detector with local feedback
US20060167074A1 (en) * 2001-06-19 2006-07-27 Norbert Muller Methods and compositions for the treatment of psychiatric disorders
DE10129320A1 (de) * 2001-06-19 2003-04-10 Norbert Mueller Verwendung von COX-2 Inhibitoren zur Behandlung von Schizophrenie, wahnhaften Störungen, affektiven Störungen oder Ticstörungen
AR038957A1 (es) 2001-08-15 2005-02-02 Pharmacia Corp Terapia de combinacion para el tratamiento del cancer
PE20030323A1 (es) * 2001-08-31 2003-05-12 Novartis Ag Composicion farmaceutica
MXPA04002242A (es) 2001-09-10 2005-03-07 Sugen Inc Derivados de 3-(4,5,6,7,-tetrahidroindol-2-ilmetiliden)-2-indolinona como inhibidores de cinasa.
US7504231B2 (en) * 2001-09-13 2009-03-17 The Board Of Regents Of The University Of Oklahoma Method of alleviating chronic pain via peripheral inhibition of neurotransmitter synthesis
US7288246B2 (en) 2001-09-13 2007-10-30 The Board Of Regents Of The University Of Oklahoma Method of alleviating chronic pain via peripheral glutaminase regulation
GB0124459D0 (en) * 2001-10-11 2001-12-05 Novartis Ag Organic compounds
CA2464309C (en) * 2001-10-25 2012-01-03 Novartis Ag Combinations comprising a selective cyclooxygenase-2 inhibitor
CA2461373A1 (en) * 2001-11-06 2003-05-15 Novartis Ag Cyclooxygenase-2 inhibitor/histone deacetylase inhibitor combination
US20030212138A1 (en) * 2002-01-14 2003-11-13 Pharmacia Corporation Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor
US20030220374A1 (en) * 2002-01-14 2003-11-27 Pharmacia Corporation Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors
GB0201520D0 (en) * 2002-01-23 2002-03-13 Novartis Ag Pharmaceutical uses
RU2318497C2 (ru) * 2002-03-07 2008-03-10 Новартис Аг Фармацевтические композиции
GB0209257D0 (en) * 2002-04-23 2002-06-05 Novartis Ag Organic compounds
JP2006501161A (ja) * 2002-06-11 2006-01-12 ニトロメッド インク． ニトロソ化および／またはニトロシル化シクロオキシゲナーゼ−２選択的阻害剤、組成物ならびに使用方法
ITMI20021391A1 (it) 2002-06-25 2003-12-29 Nicox Sa Nitroderivati di inibitori della cicloossigenasi-2
EP1531793A1 (en) 2002-07-23 2005-05-25 Novartis AG Ophtalmic ointment composition comprising a drug, an ointment base and a solubiling/dispersing agent
UY27939A1 (es) 2002-08-21 2004-03-31 Glaxo Group Ltd Compuestos
AU2003294221A1 (en) * 2002-09-13 2004-04-19 Kenneth E. Miller Method of alleviating pain via inhibition of neurotransmitter synthesis
GB0224198D0 (en) * 2002-10-17 2002-11-27 Novartis Ag Organic compounds
US7632866B2 (en) * 2002-10-21 2009-12-15 Ramot At Tel Aviv University Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators
US20040147581A1 (en) * 2002-11-18 2004-07-29 Pharmacia Corporation Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
AR042206A1 (es) 2002-11-26 2005-06-15 Novartis Ag Acidos fenilaceticos y derivados
US20040204411A1 (en) * 2002-12-17 2004-10-14 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
AU2003294883A1 (en) * 2002-12-18 2004-07-09 Novartis Ag Combinations of valsartan with cox-2 inhibitors
US7157577B2 (en) 2003-03-07 2007-01-02 Sugen Inc. 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors
TWI327913B (en) * 2003-03-12 2010-08-01 Novartis Ag Pharmaceutical composition comprising 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid
US20040220155A1 (en) * 2003-03-28 2004-11-04 Pharmacia Corporation Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith
SE0301010D0 (sv) 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
US20060135506A1 (en) * 2003-04-22 2006-06-22 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of pain, inflammation or inflammation mediated disorders
WO2004093814A2 (en) * 2003-04-22 2004-11-04 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a sodium channel blocker
WO2004093895A1 (en) * 2003-04-22 2004-11-04 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of pain, inflammation or inflammation mediated disorders
US20050159403A1 (en) * 2003-04-22 2005-07-21 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of central nervous system damage
AU2004237439B2 (en) 2003-05-07 2009-09-10 Osteologix A/S Treating cartilage/bone conditions with water-soluble strontium salts
WO2004100895A2 (en) * 2003-05-13 2004-11-25 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a peroxisome proliferator activated receptor agonist for the treatment of ischemic mediated central nervous system disorders
US20050026919A1 (en) * 2003-05-14 2005-02-03 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a cholinergic agent for the treatment of reduced blood flow or trauma to the central nervous system
US7220422B2 (en) 2003-05-20 2007-05-22 Allergan, Inc. Methods and compositions for treating eye disorders
WO2004105699A2 (en) * 2003-05-28 2004-12-09 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a cannabinoid agent for the treatment of central nervous system damage
US20050101597A1 (en) * 2003-07-10 2005-05-12 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitior and a non-NMDA glutamate modulator for the treatment of central nervous system damage
US20050014729A1 (en) * 2003-07-16 2005-01-20 Pharmacia Corporation Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith
WO2005009354A2 (en) * 2003-07-17 2005-02-03 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and an ikk inhibitor for the treatment of ischemic-mediated central nervous system disorders or injury
SA04250253B1 (ar) 2003-08-21 2009-11-10 استرازينيكا ايه بي احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن
US20050119262A1 (en) * 2003-08-21 2005-06-02 Pharmacia Corporation Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent
WO2005018563A2 (en) * 2003-08-22 2005-03-03 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a phosphodiesterase inhibitor for the treatment of ischemic mediated central nervous system disorders or injury
US20050113409A1 (en) * 2003-09-03 2005-05-26 Pharmacia Corporation Method for the prevention or treatment of pain, inflammation and inflammation-related disorders with a Cox-2 selective inhibitor in combination with a nitric oxide-donating agent and compositions therewith
MXPA06003663A (es) * 2003-10-03 2006-06-05 Pharmacia Corp Composiciones de un inhibidor selectivo de la ciclooxigenasa - 2 administrado en condiciones hipotermicas para el tratamiento de trastornos o lesion del sistema nervioso central mediados por isquemicos.
CA2541265A1 (en) * 2003-10-08 2005-04-28 Novartis Ag Pharmaceutical composition comprising 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid
CA2545731A1 (en) * 2003-11-12 2005-05-26 Pharmacia & Upjohn Company Compositions of a cyclooxygenase-2 selective inhibitor and a neurotrophic factor-modulating agent for the treatment of central nervous system mediated disorders
US7879817B2 (en) 2004-01-07 2011-02-01 Seikagaku Corporation Hyaluronic acid derivative and drug containing the same
AU2005224030B2 (en) 2004-03-23 2008-09-25 Novartis Ag Pharmaceutical compositions
TW200603792A (en) * 2004-04-23 2006-02-01 Pharmacia & Upjohn Co Llc Monotherapy for the treatment of psoriasis with cyclooxygenase-2 selective inhibitors
US7653154B2 (en) * 2004-05-25 2010-01-26 Agere Systems Inc. Method and apparatus for precomputation and pipelined selection of intersymbol interference estimates in a reduced-state Viterbi detector
US7487432B2 (en) * 2004-05-25 2009-02-03 Agere Systems Inc. Method and apparatus for multiple step Viterbi detection with local feedback
US7380199B2 (en) * 2004-05-25 2008-05-27 Agere Systems Inc. Method and apparatus for precomputation and pipelined selection of branch metrics in a reduced-state Viterbi detector
GB0415320D0 (en) 2004-07-08 2004-08-11 Astrazeneca Ab Novel compounds
GB0416508D0 (en) * 2004-07-23 2004-08-25 Merck Sharp & Dohme Therapeutic agents
GB0418830D0 (en) 2004-08-24 2004-09-22 Astrazeneca Ab Novel compounds
DE102004044827A1 (de) * 2004-09-16 2006-03-23 Bayer Cropscience Ag Jod-phenylsubstituierte cyclische Ketoenole
EP1817282B1 (en) 2004-11-23 2011-07-20 AstraZeneca AB Phenoxyacetic acid derivatives useful for treating respiratory diseases
ATE424386T1 (de) 2004-12-23 2009-03-15 Glaxo Group Ltd Pyridin-verbindungen für die behandlung von prostaglandin-vermittelten krankheiten
MX2007010186A (es) * 2005-02-22 2007-11-06 Merial Ltd Metodos para tratar selectivamente desordenes mediados por cox-2 mediante la administracion de gamma-tocoferol.
WO2006114704A2 (en) 2005-04-26 2006-11-02 Pfizer Inc. P-cadherin antibodies
US20060251702A1 (en) * 2005-05-05 2006-11-09 Cook Biotech Incorporated Implantable materials and methods for inhibiting tissue adhesion formation
DK2447283T3 (en) 2005-09-07 2015-08-31 Amgen Fremont Inc Human monoclonal antibodies to activin receptor-like kinase 1 (ALK-1)
US8148572B2 (en) 2005-10-06 2012-04-03 Astrazeneca Ab Compounds
TW200745003A (en) 2005-10-06 2007-12-16 Astrazeneca Ab Novel compounds
JP2007275193A (ja) * 2006-04-04 2007-10-25 Fujifilm Corp 光プローブおよび光断層画像化装置
AR061623A1 (es) 2006-06-26 2008-09-10 Novartis Ag Derivados de acido fenilacetico
GB0704407D0 (en) 2007-03-07 2007-04-18 Glaxo Group Ltd Compounds
UA100983C2 (ru) 2007-07-05 2013-02-25 Астразенека Аб Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты
US7943658B2 (en) * 2007-07-23 2011-05-17 Bristol-Myers Squibb Company Indole indane amide compounds useful as CB2 agonists and method
US8765815B2 (en) * 2007-09-20 2014-07-01 Ramot At Tel-Aviv University Ltd. N-phenyl anthranilic acid derivatives and uses thereof
US20090082452A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched lumiracoxib
US8168678B2 (en) 2008-02-01 2012-05-01 Panmira Pharmaceuticals, Inc. N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors
US8242145B2 (en) 2008-02-14 2012-08-14 Panmira Pharmaceuticals, Llc Cyclic diaryl ether compounds as antagonists of prostaglandin D2 receptors
WO2009108720A2 (en) 2008-02-25 2009-09-03 Amira Pharmaceuticals, Inc. Antagonists of prostaglandin d2 receptors
EP2268611A2 (en) 2008-04-02 2011-01-05 Amira Pharmaceuticals, Inc. Aminoalkylphenyl antagonists of prostaglandin d2 receptors
BRPI0913930A2 (pt) 2008-07-03 2015-10-20 Amira Pharmaceuticals Inc antagonistas de receptores de prostaglandinas d2
GB0813142D0 (en) 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
GB0813144D0 (en) 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
GB2463788B (en) 2008-09-29 2010-12-15 Amira Pharmaceuticals Inc Heteroaryl antagonists of prostaglandin D2 receptors
US8378107B2 (en) 2008-10-01 2013-02-19 Panmira Pharmaceuticals, Llc Heteroaryl antagonists of prostaglandin D2 receptors
WO2010042652A2 (en) 2008-10-08 2010-04-15 Amira Pharmaceuticals, Inc. Heteroalkyl biphenyl antagonists of prostaglandin d2 receptors
EP2177215A1 (en) 2008-10-17 2010-04-21 Laboratorios Del. Dr. Esteve, S.A. Co-crystals of tramadol and NSAIDs
WO2010056741A2 (en) * 2008-11-12 2010-05-20 Auspex Pharmaceuticals, Inc. Phenylacetic acid inhibitors of cyclooxygenase
WO2010057118A2 (en) 2008-11-17 2010-05-20 Amira Pharmaceuticals, Inc. Heterocyclic antagonists of prostaglandin d2 receptors
WO2011012622A1 (en) 2009-07-30 2011-02-03 Glaxo Group Limited Benzoxazinone derivatives for the treatment of glytl mediated disorders
CN102596199A (zh) 2009-07-31 2012-07-18 潘米拉制药公司 Dp2受体拮抗剂的眼用医药组合物
US8815917B2 (en) 2009-08-05 2014-08-26 Panmira Pharmaceuticals, Llc DP2 antagonist and uses thereof
WO2011023753A1 (en) 2009-08-27 2011-03-03 Glaxo Group Limited Benzoxazine derivatives as glycine transport inhibitors
JP2013516475A (ja) * 2010-01-06 2013-05-13 アミラ ファーマシューティカルズ，インク． Ｄｐ２アンタゴニストおよびその使用
GB201000685D0 (en) 2010-01-15 2010-03-03 Glaxo Group Ltd Novel compounds
GB201007791D0 (en) 2010-05-10 2010-06-23 Glaxo Group Ltd Novel compounds
GB201007789D0 (en) 2010-05-10 2010-06-23 Glaxo Group Ltd Novel Compound
ES2529233T3 (es) 2010-07-09 2015-02-18 Convergence Pharmaceuticals Limited Compuestos tetrazol como bloqueadores de canales de calcio
RU2439053C1 (ru) * 2010-08-03 2012-01-10 Государственное образовательное учреждение высшего профессионального образования "Пермский государственный университет" Диариламины и способ их получения
US8892989B1 (en) * 2010-08-26 2014-11-18 Clearslide, Inc. Method for searching companies and people
US20120090486A1 (en) 2010-10-18 2012-04-19 Celin Savariar-Hauck Lithographic printing plate precursors and methods of use
US8900798B2 (en) 2010-10-18 2014-12-02 Eastman Kodak Company On-press developable lithographic printing plate precursors
US20120141935A1 (en) 2010-12-03 2012-06-07 Bernd Strehmel Developer and its use to prepare lithographic printing plates
US20120141942A1 (en) 2010-12-03 2012-06-07 Domenico Balbinot Method of preparing lithographic printing plates
US20120141941A1 (en) 2010-12-03 2012-06-07 Mathias Jarek Developing lithographic printing plate precursors in simple manner
ES2541416T3 (es) 2011-01-19 2015-07-20 Convergence Pharmaceuticals Limited Derivados de piperazina como bloqueadores de los canales de calcio Cav2.2
US20120199028A1 (en) 2011-02-08 2012-08-09 Mathias Jarek Preparing lithographic printing plates
WO2013037705A2 (en) 2011-09-16 2013-03-21 Fovea Pharmaceuticals Aniline derivatives,their preparation and their therapeutic application
US9029063B2 (en) 2011-09-22 2015-05-12 Eastman Kodak Company Negative-working lithographic printing plate precursors
US8632941B2 (en) 2011-09-22 2014-01-21 Eastman Kodak Company Negative-working lithographic printing plate precursors with IR dyes
CN102311355B (zh) * 2011-09-26 2014-02-05 扬州天和药业有限公司 罗本考昔的一种制备方法
GB201122113D0 (en) 2011-12-22 2012-02-01 Convergence Pharmaceuticals Novel compounds
US8679726B2 (en) 2012-05-29 2014-03-25 Eastman Kodak Company Negative-working lithographic printing plate precursors
US9063423B2 (en) 2013-02-28 2015-06-23 Eastman Kodak Company Lithographic printing plate precursors and use
US9201302B2 (en) 2013-10-03 2015-12-01 Eastman Kodak Company Negative-working lithographic printing plate precursor
GB201417497D0 (en) 2014-10-03 2014-11-19 Convergence Pharmaceuticals Novel use
GB201417499D0 (en) 2014-10-03 2014-11-19 Convergence Pharmaceuticals Novel use
GB201417500D0 (en) 2014-10-03 2014-11-19 Convergence Pharmaceuticals Novel use
WO2018049015A1 (en) 2016-09-07 2018-03-15 Trustees Of Tufts College Combination therapies using immuno-dash inhibitors and pd-1 antagonists
BR112019018172A2 (pt) 2017-03-14 2020-04-07 Seikagaku Kogyo Co Ltd composição para tratar uma doença de articulação humana, e, kit.
MY195178A (en) 2017-03-14 2023-01-11 Seikagaku Kogyo Co Ltd Composition for Treating Joint Disease and Kit Containing Same
KR102069205B1 (ko) 2017-08-09 2020-01-22 연성정밀화학(주) 라타노프로스틴 부노드의 제조 방법 및 그를 위한 중간체
CN109694330B (zh) * 2017-10-24 2023-10-20 乳源瑶族自治县东阳光生物科技有限公司 一种酸的制备方法
EP3830072A1 (en) 2018-07-27 2021-06-09 KRKA, d.d., Novo mesto A process for the preparation of polymorphic form of robenacoxib
CN109503399B (zh) * 2018-12-29 2021-12-24 江苏天和制药有限公司 一种罗本考昔的制备方法
CN110437090A (zh) * 2019-07-31 2019-11-12 江苏天和制药有限公司 一种罗本考昔三聚体及其制备方法
CN111807978B (zh) * 2020-07-29 2023-03-14 武汉川泰科技有限公司 一种罗贝考昔的制备方法
WO2022195579A1 (en) 2021-03-15 2022-09-22 Saul Yedgar Hyaluronic acid-conjugated dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (nsaids) for treating or alleviating inflammatory diseases
WO2023181053A1 (en) 2022-03-23 2023-09-28 Alivira Animal Health Limited An improved process for purification of robenacoxib

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3895063A (en) 1965-04-08 1975-07-15 Ciba Geigy Corp Substituted Anilino Benzyl Alcohols
US3558690A (en) 1965-04-08 1971-01-26 Gelgy Chemical Corp Substituted derivatives of 2-anilinophenylacetic acids and a process of preparation
GB1166861A (en) 1966-01-15 1969-10-15 Aspro Nicholas Ltd New Diphenylamine Derivatives and Compositions containing them
US3652762A (en) 1970-04-14 1972-03-28 Ciba Geigy Corp Pharmaceutical compositions and methods employing substituted derivatives of 2-anilinophenylacetic acids and esters
US4173577A (en) 1970-09-09 1979-11-06 Ciba-Geigy Corporation Phenylacetohydroxamic acids
ES520813A0 (es) 1983-03-21 1984-05-16 Prodes Sa Procedimiento para la obtencion del ester del acido 2-(2,6-diclorofenil)amino bencenoacetico con acido glicolico.
DE3445011A1 (de) 1983-12-13 1985-06-13 Ciba-Geigy Ag, Basel Neues anilinderivat, verfahren zu seiner herstellung und seine verwendung
GR900100380A (el) * 1989-05-20 1991-10-10 Fisons Plc Μέ?οδος παρασκευής αντι-φλεγμονωδών παραγώγων αμινοφενόλης.
IT1256345B (it) 1992-08-20 1995-12-01 Esteri nitrici di derivati dell'acido 2-(2,6-di-alo-fenilammino) fenilacetico e procedimento per la loro preparazione
MX9700210A (es) 1994-06-29 1998-01-31 Novartis Ag Tambien Denominada Nuevas sales de acido 2-((2,6-diclorofenil) amina)fenilacetoxiacetico con cationes basicos organicos.
JPH0977664A (ja) 1995-09-13 1997-03-25 Yakult Honsha Co Ltd シクロオキシゲナーゼ−２特異的阻害剤及び抗炎症剤
CO4960662A1 (es) * 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados

Also Published As

Publication number Publication date
CN1140500C (zh) 2004-03-03
AR015157A1 (es) 2001-04-18
SK2472000A3 (en) 2000-09-12
LU91540I2 (fr) 2009-05-11
SI1007505T1 (en) 2003-10-31
JP2001514244A (ja) 2001-09-11
KR20010023344A (ko) 2001-03-26
US6727281B2 (en) 2004-04-27
DE122007000035I2 (de) 2010-07-01
TR200000447T2 (tr) 2000-07-21
MY127881A (en) 2006-12-29
ES2197508T3 (es) 2004-01-01
CY2007020I1 (el) 2012-01-25
NL300379I1 (nl) 2009-05-06
AU9534098A (en) 1999-03-22
CZ2000714A3 (cs) 2000-06-14
AU743371B2 (en) 2002-01-24
TWI250142B (en) 2006-03-01
HUP0002514A3 (en) 2002-11-28
EP1007505A1 (en) 2000-06-14
NO326196B1 (no) 2008-10-13
DE69813570D1 (de) 2003-05-22
PL194480B1 (pl) 2007-06-29
CZ298522B6 (cs) 2007-10-24
NO2009007I2 (no) 2010-06-07
IL134498A (en) 2009-06-15
NZ502669A (en) 2002-02-01
ID23953A (id) 2000-06-08
HU225774B1 (en) 2007-08-28
RU2186762C2 (ru) 2002-08-10
CA2298033C (en) 2007-10-02
PL338357A1 (en) 2000-10-23
US20040122254A1 (en) 2004-06-24
BR9812010A (pt) 2000-12-12
IL134498A0 (en) 2001-04-30
KR100637296B1 (ko) 2006-10-23
DK1007505T3 (da) 2003-07-21
DE122007000035I1 (de) 2007-07-19
US7115662B2 (en) 2006-10-03
US20020013369A1 (en) 2002-01-31
CA2298033A1 (en) 1999-03-11
CY2007020I2 (el) 2012-01-25
HUP0002514A2 (hu) 2000-12-28
SK283773B6 (sk) 2004-01-08
FR09C0011I2 (no) 2011-04-01
PE108099A1 (es) 1999-11-18
US6291523B1 (en) 2001-09-18
NO20000943D0 (no) 2000-02-25
US20020183391A1 (en) 2002-12-05
PT1007505E (pt) 2003-08-29
US6310099B1 (en) 2001-10-30
WO1999011605A1 (en) 1999-03-11
JP3704470B2 (ja) 2005-10-12
CN1268112A (zh) 2000-09-27
NL300379I2 (nl) 2010-02-01
LU91346I2 (fr) 2007-09-11
NO20000943L (no) 2000-02-25
DE69813570T2 (de) 2004-02-12
HK1031374A1 (en) 2001-06-15
CO4960662A1 (es) 2000-09-25
DE122009000013I1 (de) 2009-06-25
FR09C0011I1 (no) 2009-04-17
ATE237580T1 (de) 2003-05-15
EP1007505B1 (en) 2003-04-16
BR9812010B1 (pt) 2010-12-14
WO1999011605A8 (en) 2000-03-02
US6451858B2 (en) 2002-09-17

Similar Documents

Publication Publication Date Title
NO2009007I1 (no) Robenakoksib, et salt, en ester eller prodrug derav
ATE251173T1 (de) 4ß-SUBSTITUTIERTE-9-DEOXO-9A-AZA-9A- HOMOERYTHROMYCIN A DERIVATE
ID25548A (id) Senyawa-senyawa heterosiklik spiroazabisiklik terbaru
DE69832369D1 (de) Hämofiltrationssystem
NO2011007I1 (no) Ticagrelor eller et farmasøytisk akseptabelt salt derav
FI973892A0 (fi) Foerfarande och anordning foer att foerbaettra laecktoleransen i en hoerlur
EP0953464A4 (en) LOUVRE
DE69829636D1 (de) Durchgefärbtes pauspapier
DE19756119B4 (de) Heftvorrichtung
ID20656A (id) Ko-produksi ester
FR2768938B1 (fr) Raquette a neige
ID21536A (id) Pembuatan ester
FR2760375B1 (fr) Raquette a neige
DE59810608D1 (de) Stapelvorrichtung
DE69815029D1 (de) Heftvorrichtung
DE69812851D1 (de) Heftvorrichtung
FI974093A0 (fi) Foerfarande och anordning foer att byta en vaevnad i en pappersmaskin
DE59805449D1 (de) Verdrängerpumpe
DE59907734D1 (de) Emulgatoren
DE69805245D1 (de) Heftvorrichtung
FI974042L (fi) Menetelmä kartonkiliuskan tai vastaavan jatkamiseksi
FI973700A0 (fi) Foerfarande och anordning foer att oevervaka en apparatur
ID20763A (id) Mesin tenun
FI972196A0 (fi) Kalander
UA25695A (uk) Сталебетоhhа шпреhгельhа балка

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: NOVARTIS TIERGESUNDHEIT AG, CH

CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: ELANCO TIERGESUNDHEIT AG, CH